Midostaurin in Advanced Systemic Mastocytosis

The use of midostaurin, a multikinase inhibitor, has been associated with a response in 60% of patients with systemic mastocytosis, including mast-cell leukemia; the median overall survival was 28 months. A second, smaller trial in France showed a 71% response rate.